Hims & Hers Health's $1.26B Volume Ranks 67th in U.S. as Stock Plunges 4.91%

On September 24, 2025, Hims & Hers Health (HIMS) saw a trading volume of $1.26 billion, ranking 67th among U.S. stocks for the day. The stock closed down 4.91%, reflecting mixed investor sentiment amid evolving business dynamics.

Hims & Hers Health, a telehealth platform offering services in mental health, dermatology, and sexual wellness, reported a 110% year-over-year revenue increase in Q1 2025. However, the company faces challenges in its weight loss segment following the FDA’s resolution of compounded drug shortages, which previously fueled growth. Strategic shifts toward oral medications and international expansion, including the acquisition of Zava to enter European markets, highlight efforts to diversify revenue streams.

The company’s profitability improved, with $50 million in free cash flow during Q1, despite a 7% quarterly revenue decline. While Hims & Hers remains a large-cap player with a $10.8 billion market value, its reliance on recurring subscriptions and telehealth scalability positions it for long-term growth. Analysts note that the stock’s recent performance is influenced by sector-specific trends and competitive pressures in the healthcare technology space.

To run this properly I first need to pin down a couple of details that aren’t explicit in the request and that will determine whether I can automate it end-to-end with the available tool set:

1. Universe definition • Do you want “all U.S. listed common stocks” (≈ 6 000 names) or a narrower set such as the Russell 3000, S&P 1500, etc.? • ADRs, ETFs and penny stocks – include or exclude?

2. Weighting and re-balancing convention • Equal-weight across the 500 names each day (default), or volume-/value-weight? • Entry/exit price – buy at today’s close and sell at tomorrow’s close (default), or use opens?

3. Practical scale The current back-test engine can process a single instrument or an event list for one instrument at a time. A “top-500-every-day” strategy is effectively a 500-stock portfolio that rebalances daily. To reproduce that faithfully I would have to construct an aggregated return series outside the built-in engine, which is feasible but more involved.

Two pragmatic alternatives are: • Run the test on a narrower slice (e.g. top-50 by volume) so we can scrape and process all data instrument-by-instrument; or • Treat the strategy as “buy the high-volume bucket of a broad universe” and approximate it with an equal-weight index we build and feed into the engine.